logo-loader
viewSocial Reality, Inc.

Digital ad agency Social Reality sells its healthcare and pharmaceutical line for up to US$52.5mln

Private equity firm Halyard Capital plans to purchase the product line

Phone and tablet on a table
The digital marketing company also operates Big Token, a blockchain-based technology platform

Digital marketing company Social Reality Inc (NASDAQ:SRAX) has agreed to sell a controlling interest in SRAXmd, its healthcare and pharmaceutical digital advertising line.

The product line will be sold to an affiliate of private equity firm Halyard Capital for up to US$52.5mln, according to the company’s press release.

WATCH: Social Reality Inc to launch beta of blockchain identification graph technology platform soon

“This transaction gives us the benefit of the long-term growth we have been experiencing in MD, which we believe will be worth significantly more in the future while providing us the capital we need to grow our other verticals and to bring Big Token to market,” said CEO Christopher Miglino in a statement.

The company operates a digital marketing and data management platform, analyzing marketing data through the use of AI to identify core consumers. Big Token is the company’s blockchain-based identification graph technology platform.

The Los Angeles-based company joined the Russell Microcap Index in June.

Shares of the advertising company were up more than 15% to US$6.49 in Monday pre-market trading.

Quick facts: Social Reality, Inc.

Price: 2.415 USD

NASDAQ:SRAX
Market: NASDAQ
Market Cap: $33.8 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Revenue guidance from OptiBiotix as it eyes NASDAQ listing

OptiBiotix Health (LON:OPTI) provides a commercial progress update, explaining why in their financials some items are separated. CEO Stephen O'Hara tells Proactive London what's behind his thinking adding that Optibiotix hopes to reach profitability in 2020. News here too on Sweetbiotix and...

1 day, 3 hours ago

2 min read